ISPOR - CO95 Growing Acceptance of Minimal Residual Disease (MRD) As a Primary Endpoint in Multiple Myeloma (MM) Clinical Trials

CO95 Growing Acceptance of Minimal Residual Disease (MRD) As a Primary Endpoint in Multiple Myeloma (MM) Clinical Trials

Abstract

Authors

C. Jones AT. Watson Z. Wolkensdorfer

Full Text Cite This Article

Back to Volume 27, Supplemental Issue 6S

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now